MEDIPHARM LABS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 CAD | 0.00% |
|
+6.67% | +23.08% |
| 27/03 | MediPharm Labs Narrows Q4 Loss, Revenue Grows; Up 10.5% | MT |
| 27/03 | MediPharm Labs Narrows Q4 Loss, Revenue Grows | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company's Refinitiv ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +23.08% | 23.68M | D | ||
| +37.08% | 6.01B | B- | ||
| -17.43% | 4.4B | C+ | ||
| -9.46% | 3.17B | B- | ||
| +0.51% | 3.07B | C | ||
| -3.53% | 2.51B | - | D+ | |
| +41.15% | 1.88B | - | ||
| -5.15% | 1.73B | - | - | |
| +0.09% | 1.65B | - | - | |
| -10.38% | 1.58B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LABS Stock
- Ratings MediPharm Labs Corp.
